Influence of switching from dulaglutide to oral semaglutide on glycaemic control and clinical parameters in Japanese patients with well-controlled type 2 diabetes: a retrospective, observational study
DOI:
https://doi.org/10.15277/bjd.2025.492Keywords:
dulaglutide, oral semaglutide, switching, dulaglutide supply insufficiency, high-density lipoprotein cholesterol, gamma-glutamyl transferaseAbstract
Aims: This study sought to evaluate retrospectively how switching from dulaglutide to oral semaglutide affected glycaemic control and clinical parameters in patients with well-controlled type 2 diabetes (T2DM).
Methods: The study included 18 patients with well-controlled T2DM (mean HbA1c 6.99%) who were taking dulaglutide. HbA1c levels and clinical parameters were measured at baseline and two, four and six months later. Changes in these parameters during the study period were assessed retrospectively.
Results: HbA1c levels at two months from baseline were significantly higher than at baseline (7.43 ± 0.72 vs. 6.99 ± 0.39%, p = 0.003), whereas no significant change was observed at four or six months from baseline. Subjects with improved glycaemic control at six months from baseline (n = 5) had significantly lower gamma-glutamyl transferase levels at baseline compared to those who did not show improvement (n = 13) (13.8 ± 3.0 vs. 47.9 ± 53.6 IU/L, p = 0.026). Notably, high-density lipoprotein cholesterol levels at six months were significantly higher than at baseline (p = 0.006).
Conclusion: Glycaemic control worsened temporarily after switching from dulaglutide to oral semaglutide, but no significant difference was observed between baseline and six months later.
References
American Diabetes Association professional practice committee. Erratum. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024. Diabetes Care 2024;47:S158-78. https://doi.org/10.2337/dc24-S009
Han SH, Safeek R, Ockerman K, et al. Public interest in the off-label use of glucagon-like peptide 1 agonists (Ozempic) for cosmetic weight loss: a Google trends analysis. Aesthet Surg J 2023;44:60-7. https://doi.org/10.1093/asj/sjad211.
Whitley HP, Trujillo JM, Neumiller JJ. Special report: potential strategies for addressing GLP-1 and dual GLP-1/GIP receptor agonist shortages. Clin Diabetes 2023;41:467-73. https://doi.org/10.2337/cd23-0023
Matsuo S, Imai E, Horio M, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982-92. https://doi.org/10.1053/j.ajkd.2008.12.034
Umemura S, Arima H, Arima S, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res 2019;42:1235-81. https://doi.org/10.1038/s41440-019-0284-9
Yabe D, Nakamura J, Kaneto H, et al. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol 2020; 8:392-406. https://doi.org/10.1016/S2213-8587(20)30074-7
Watanabe K, Oba K, Suzuki T, et al. Glucose levels during oral glucose tolerance tests and gamma-glutamyl transpeptidase are predictors of change from normal to impaired glucose tolerance in healthy middle-aged Japanese men. Acta Diabetol 2010;47:225-30. https://doi.org/10.1007/s00592-009-0122-7
Zhao W, Tong J, Liu J, et al. The dose-response relationship between gamma-glutamyl transferase and risk of diabetes mellitus using publicly available data: a longitudinal study in Japan. Int J Endocrinol 2020;2020:5356498. https://doi.org/10.1155/2020/5356498
Yokoyama H, Hirose H, Moriya S, et al. Significant correlation between insulin resistance and serum gamma-glutamyl transpeptidase (gamma-GTP) activity in non-drinkers. Alcohol Clin Exp Res 2002;26(8 Suppl):91S-4S. https://doi.org/10.1097/01.ALC.0000027029.69966.E3
Zoppini G, Targher G, Trombetta M, et al. Relationship of serum gamma-glutamyltransferase to atherogenic dyslipidemia and glycemic control in type 2 diabetes. Obesity (Silver Spring) 2009;17:370-4. https://doi.org/10.1038/oby.2008.544
Zheng J, Hu Y, Xu H, et al. Normal-weight visceral obesity promotes a higher 10-year atherosclerotic cardiovascular disease risk in patients with type 2 diabetes mellitus–a multicenter study in China. Cardiovasc Diabetol 2023;22:137. https://doi.org/10.1186/s12933-023-01876-7
Wu L, Zhang M, Hu H, et al. Elevated gamma-glutamyl transferase has a non-linear association with incident non-alcoholic fatty liver disease in the non-obese Chinese population: a secondary retrospective study. Lipids Health Dis 2021;20:142. https://doi.org/10.1186/s12944-021-01577-8
Forlano R, Stanic T, Jayawardana S, et al. A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community. Cost effectiveness of screening strategies. Liver Int 2024;44:61-71. https://doi.org/10.1111/liv.15730
Das Pradhan A, Glynn RJ, Fruchart JC, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med 2022; 387:1923-34. https://doi.org/10.1056/NEJMoa2210645
Gabani M, Shapiro MD, Toth PP. The role of triglyceride-rich lipoproteins and their remnants in atherosclerotic cardiovascular disease. Eur Cardiol 2023;18:e56. https://doi.org/10.15420/ecr.2023.16
Christou GA, Kiortsis DN. Adiponectin and lipoprotein metabolism. Obes Rev 2013;14:939-49. https://doi.org/10.1111/obr.12064.
von Eynatten M, Schneider JG, Humpert PM, et al. Decreased plasma lipoprotein lipase in hypoadiponectinemia: an association independent of systemic inflammation and insulin resistance. Diabetes Care 2004;27:2925-9. https://doi.org/10.2337/diacare.27.12.2925.
Al Refaie A, Baldassini L, Mondillo C, et al. Adiponectin may play a crucial role in the metabolic effects of GLP-1RAs treatment in patients with type 2 diabetes mellitus: a preliminary longitudinal study. Endocrine 2025;87(3):951-8. https://doi.org/10.1007/s12020-024-04085-8.
Sacks FM; Expert group on HDL cholesterol. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002;9:139-43. https://doi.org/10.1016/s0002-9149(02)02436-0
Ishii H, Shin K, Tosaki T, et al. Reproducibility and validity of a questionnaire measuring treatment burden on patients with type 2 diabetes: Diabetic Treatment Burden Questionnaire (DTBQ). Diabetes Ther 2018;9:1001-19. https://doi.org/10.1007/s13300-018-0414-4.
Hashimoto Y, Yasuzawa H, Ishida T, et al. A survey on consciousness towards the proper use of metformin and medical cost in Japanese patients with type 2 diabetes. J Clin Biochem Nutr 2021;69:286-93. https://doi.org/10.3164/jcbn.21-5
Hansen BB, Nuhoho S, Ali SN, et al. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis. J Med Econ 2020;23:650-8. https://doi.org/10.1080/13696998.2020.1722678
Takahara M, Shiraiwa T, Katakami N, et al. Daily glucose profiles after switching from Injectable to oral semaglutide in patients with type 2 diabetes mellitus. Intern Med 2024;63:43-50. https://doi.org/10.2169/internalmedicine.1441-22
Ishii H, Hansen BB, Langer J, et al. Effect of orally administered semaglutide versus dulaglutide on diabetes-related quality of life in Japanese patients with type 2 diabetes: the PIONEER 10 Randomized, Active-Controlled Trial. Diabetes Ther 2021;12:613-23. https://doi.org/10.1007/s13300-020-00985-w
Al OM. Diabetes care and control: the effect of frequent visits to diabetes care center. Ann Saudi Med 2014;34:229-234. https://doi.org/10.5144/0256-4947.2014.229
Norris SL, Lau J, Smith SJ, et al. Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control. Diabetes Care 2002;25:1159-1171.
Published
Issue
Section
License
Copyright (c) 2025 British Journal of Diabetes
This work is licensed under a Creative Commons Attribution 4.0 International License.
Manuscripts published in the June 2024 edition and after in the BJD have been published in open access under a Creative Commons Attribution 4.0 International License and available at https://www.bjd-abcd.com. Prior year articles are available free of charge via our website.
